Long‐term evolving profile of childhood autoimmune blistering diseases Retrospective study on 38 children

Abstract

Background

Autoimmune bullous dermatosis (AIBDs) in children are uncommon and their long‐term evolution remains unknown.

Objective

The aim of this retrospective study was to characterize the long‐term prognosis of AIBDs that started during childhood.

Methods

We conducted a monocentric retrospective study, in the French dermatology center, by including all children affected by AIBDs. The long‐term outcome was obtained through a phone call questionnaire.

Results

63 patients were included from January 1993 to December 2015, 34 female and 29 males: 27 Linear immunoglobulin A disease (LAD), 12 bullous pemphigoid (BP), 12 pemphigus, 8 herpetiform dermatitis (DH) and 4 epidermolysis bullosa aquisita (EBA). The mean age was 4.7 years old. 25 patients were lost during the follow‐up. For the 38 remaining patients, the mean follow‐up duration for all pathologies was 6.6 years. 29 of them had at least one relapse. Late relapses were observed in 2 cases of DH and 6 cases of pemphigus (7 ‐ 34 months). The mean treatment duration was 30.6 months with variability according to the AIBDs. Topical corticosteroids were used alone, effectively, for 7 patients and in association with other treatment in 19 patients in complete remission. Complete remission was noted in 34/38 children with a follow‐up of 4.4 years (0.08‐19.5). The mean duration to complete remission was 30.5 months (6‐114 months). Late nasal synechiae were reported in one EBA only. There was no significant associated comorbidity, but an association with a primary immune deficiency (PID) was observed in 2 cases.

Conclusion

Childhood AIBDs appear to be of good overall prognosis but a long‐term follow‐up is mandatory, as relapses can be late, except for BP. The use of topical corticosteroids is frequently effective alone or in association. The association with PID leads to think about the possibility of a possible underlying dysimmunity in the child.

This article is protected by copyright. All rights reserved.

http://bit.ly/2RZFdAu